Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-EXT long-term open-label methylone in PTSD
2023-508381-16-00Phase 2Completed
- Sponsor
- Transcend Therapeutics
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of methylone in post-traumatic stress disorder (PTSD), sponsored by Transcend Therapeutics. Primary endpoints: Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score, PTSD Checklist for DSM-5 (PCL-5) and 10 more. Started Apr 2024; status: completed.
02
Drugs
methylone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2023-508381-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508381-16-00.